#4 - Beam Therapeutics (NASDAQ:BEAM)
To this point, we’ve put the focus on companies that are using some form of CRISPR/Cas9 technology. Beam Therapeutics, Inc. (NASDAQ: BEAM) takes a different approach to gene editing. Specifically, Beam is engaged in base editing.
In the human genome, there are four types of bases found in DNA that form the “letters” that make up our genetic code. A “point mutation” occurs when these base pairs are “misspelled.” Point mutations are frequently a marker for the disease. Beam Therapeutics is attempting to use a “molecular pencil” to erase and rewrite these point mutations as opposed to splicing it out.
The company’s lead candidate, BEAM-101 is being developed to treat sickle cell disease and beta-thalassemia and is in ealry clinical trials. That means it will likely still be years before investors can plan on meaningful revenue and earnings.
BEAM stock has a Moderate Buy rating from the analysts surveyed by MarketBeat and has 76% institutional ownership.
About Beam Therapeutics
Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.
Read More - Current Price
- $29.01
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 8 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $47.67 (64.3% Upside)
